Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Evgeny Arons"'
Autor:
Filippo Vit, Tamara Bittolo, Robel Papotti, Federico Pozzo, Antonella Zucchetto, Erika Tissino, Eva Zaina, Ilaria Catarossi, Roberta Laureana, Jacopo Olivieri, Pietro Bulian, Luciano Levato, Giovanni D’arena, Daniele Armiento, Alberto Zamò, Ellen Leich, Andreas Rosenwald, Evgeny Arons, Robert J. Kreitman, Massimo Gentile, Luca Laurenti, Francesco Zaja, Agostino Tafuri, Annalisa Chiarenza, Maria Ilaria DEL Principe, Valter Gattei, Riccardo Bomben
Publikováno v:
HemaSphere, Vol 7, p e939603e (2023)
Externí odkaz:
https://doaj.org/article/1f2fdc79ac704c13806da116d5de49c9
Autor:
Evgeny Arons, Hong Zhou, Mark Sokolsky, Daniel Gorelik, Katherine Potocka, Sarah Davies, Erin Fykes, Katherine Still, Daniel C Edelman, Yonghong Wang, Paul S Meltzer, Mark Raffeld, Adrian Wiestner, Liqiang Xi, Hao-Wei Wang, Maryalice Stetler-Stevenson, Constance Yuan, Robert J Kreitman
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0227586 (2020)
Hairy cell leukemia (HCL) is a purine analog-responsive B-cell malignancy containing the BRAF V600E mutation, expressing CD22, CD11c, CD103, tartrate resistant acid phosphatase (TRAP) CD25, CD123, and annexin 1A. BRAF V600E and the latter 4 markers a
Externí odkaz:
https://doaj.org/article/b4c3619133ba44569ecd584f874b3177
Autor:
A. Rouf Banday, Megan L. Stanifer, Oscar Florez-Vargas, Olusegun O. Onabajo, Brenen W. Papenberg, Muhammad A. Zahoor, Lisa Mirabello, Timothy J. Ring, Chia-Han Lee, Paul S. Albert, Evangelos Andreakos, Evgeny Arons, Greg Barsh, Leslie G. Biesecker, David L. Boyle, Mark S. Brahier, Andrea Burnett-Hartman, Mary Carrington, Euijin Chang, Pyoeng Gyun Choe, Rex L. Chisholm, Leandro M. Colli, Clifton L. Dalgard, Carolynn M. Dude, Jeff Edberg, Nathan Erdmann, Heather S. Feigelson, Benedito A. Fonseca, Gary S. Firestein, Adam J. Gehring, Cuncai Guo, Michelle Ho, Steven Holland, Amy A. Hutchinson, Hogune Im, Les’Shon Irby, Michael G. Ison, Naima T. Joseph, Hong Bin Kim, Robert J. Kreitman, Bruce R. Korf, Steven M. Lipkin, Siham M. Mahgoub, Iman Mohammed, Guilherme L. Paschoalini, Jennifer A. Pacheco, Michael J. Peluso, Daniel J. Rader, David T. Redden, Marylyn D. Ritchie, Brooke Rosenblum, M. Elizabeth Ross, Hanaisa P. Sant Anna, Sharon A. Savage, Sudha Sharma, Eleni Siouti, Alicia K. Smith, Vasiliki Triantafyllia, Joselin M. Vargas, Jose D. Vargas, Anurag Verma, Vibha Vij, Duane R. Wesemann, Meredith Yeager, Xu Yu, Yu Zhang, Steeve Boulant, Stephen J. Chanock, Jordan J. Feld, Ludmila Prokunina-Olsson
Publikováno v:
Nature Genetics. 54:1103-1116
The chr12q24.13 locus encoding OAS1–OAS3 antiviral proteins has been associated with coronavirus disease 2019 (COVID-19) susceptibility. Here, we report genetic, functional and clinical insights into this locus in relation to COVID-19 severity. In
Autor:
Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, Vivek Subbiah
Publikováno v:
Blood, 141(9), 996-1006. American Society of Hematology
BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive HCL. This open-label, phase 2 study enro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::382e8180680d605280f887a35fd1cfd3
https://pure.eur.nl/en/publications/dd97aa4b-41a6-4226-94e6-22fa796142f8
https://pure.eur.nl/en/publications/dd97aa4b-41a6-4226-94e6-22fa796142f8
Autor:
Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, Michael R. Grever
Publikováno v:
Blood. 140:6494-6495
Autor:
Electra Sofou, Maria Karypidou, Laura Zaragoza-Infante, Nikolaos Pechlivanis, Fotis Psomopoulos, Elisavet Georgiou, Evgeny Arons, Robert J. Kreitman, Anastasia Chatzidimitriou, Kostas Stamatopoulos
Publikováno v:
Blood. 140:6399-6400
Autor:
Jordan J. Feld, Pyoeng Gyun Choe, Rex L Chrisholm, Joselin M Vargas, Vibha Vij, Nathan Erdmann, Mary Carrington, A Rouf Banday, Sharon A. Savage, Michael G. Ison, Duane R. Wesemann, Anurag Verma, Leslie G. Biesecker, Euijin Chang, Chia-Han Lee, Gary S. Firestein, Adam J. Gehring, Lisa Mirabello, Robert J. Kreitman, Timothy J Ring, Michael J Peluso, Bruce R. Korf, Hogune Im, Yu Zhang, Daniel J. Rader, Megan L. Stanifer, Marylyn D. Ritchie, Jennifer A. Pacheco, Muhammad Atif Zahoor, Hanaisa P Sant Anna, Greg Barsh, Steeve Boulant, Meredith Yeager, Brooke Rosenbloom, Ludmila Prokunina-Olsson, David T. Redden, David L. Boyle, Olusegun O Onabajo, Evangelos Andreakos, Michelle Ho, Oscar Florez-Vargas, Heather Spencer Feigelson, Eleni Siouti, Amy Hutchinson, Xu G. Yu, Vasiliki Triantafyllia, Brenen W Papenberg, Andrea N. Burnett-Hartman, Jeffrey C. Edberg, Clifton L. Dalgard, Steven M. Holland, Evgeny Arons, Stephen J. Chanock, Hong Bin Kim
Publikováno v:
medRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
Genomic regions have been associated with COVID-19 susceptibility and outcomes, including the chr12q24.13 locus encoding antiviral proteins OAS1-3. Here, we report genetic, functional, and clinical insights into genetic associations within this locus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dec1a13dc7d8e808d3b9532e357ddc3
https://doi.org/10.1101/2021.07.09.21260221
https://doi.org/10.1101/2021.07.09.21260221
Autor:
Robert J. Kreitman, Evgeny Arons
Publikováno v:
Blood Reviews
Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients
Autor:
Hong Zhou, Julie Feurtado, Hao-Wei Wang, Seth M. Steinberg, Chin-Hsien Tai, Mark Raffeld, Constance M. Yuan, Lacey James-Echenique, Evgeny Arons, Raul C. Braylan, Dai Chihara, Liqiang Xi, Alina Dulau-Florea, Katherine R. Calvo, Robert J. Kreitman, Keyur P. Patel, Maryalice Stetler-Stevenson, Irina Maric
Publikováno v:
Blood advances. 5(23)
Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy. Rituximab concurrent with cladribine (CDAR) improves response rates, but long-term outcomes are unknown. We report final results of a phase 2 study of CDAR for patient
Autor:
Liqiang Xi, Robert J. Kreitman, Constance M. Yuan, Hong Zhou, Lacey R. James, Mark Raffeld, Hao-Wei Wang, Seth M. Steinberg, Katherine R. Calvo, Evgeny Arons, Wyndham H. Wilson, Alina Dulau-Florea, Julie Feurtado, Irina Maric, Raul C. Braylan, Dai Chihara, Maryalice Stetler-Stevenson
Publikováno v:
J Clin Oncol
PURPOSE Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeat